Ibuprofen

證據等級: L5

預測適應症: 10 個

Ibuprofen: From Pain and Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID), traditionally indicated for pain, fever and inflammation. The TxGNN model’s top prediction for this drug is acromesomelic dysplasia, Hunter-Thompson type, a rare skeletal dysplasia — but this prediction is supported by zero clinical trials and zero publications, and the evidence pack itself flags the mechanistic link as likely noise from knowledge-graph embedding proximity rather than genuine biological plausibility.

Quick Overview

Item	Content
Original Indication	Pain, fever and inflammation (NSAID) — general pharmacological knowledge; no approved-indication text is available in this dataset (drug is not marketed, 0 licences on file)
Predicted New Indication	Acromesomelic dysplasia, Hunter-Thompson type
TxGNN Prediction Score	99.74%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (marked as a data gap). Based on general pharmacological knowledge, ibuprofen is a COX-1/COX-2 inhibitor that reduces prostaglandin synthesis, producing analgesic, antipyretic and anti-inflammatory effects.

Acromesomelic dysplasia, Hunter-Thompson type is a rare skeletal disorder caused by GDF5 gene mutations, with a pathology rooted in abnormal endochondral ossification — a developmental process, not an inflammation-driven one. The evidence pack’s own rationale is explicit on this point: there is no known mechanistic pathway connecting COX inhibition to the skeletal growth-factor signalling involved in this condition, and it characterises the very high TxGNN score as most likely reflecting proximity in the model’s embedding space rather than a genuine biological relationship.

In short, this prediction currently has no mechanistic, preclinical or clinical support. The other nine candidates in this evidence pack (rank 2–10) are similarly rare genetic/developmental syndromes scored L5 with no supporting trials or literature, several with rationale text explicitly describing the mechanistic link as “theoretical” or “unproven.” None of the ten candidates in this pack currently rise above model-prediction-only status.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Ibuprofen is recorded as not marketed in this dataset, with 0 ARTG-equivalent licence entries on file. No product/dosage-form information is available to tabulate.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has no clinical trial or literature support, and the evidence pack itself identifies the mechanistic rationale as biologically implausible (likely embedding-proximity noise rather than a real drug–disease relationship). Combined with the absence of market/registration data for this drug, there is currently no basis to advance this candidate.

To proceed, the following is needed:

TFDA/TGA-approved product information (warnings, contraindications) — currently a blocking data gap
Confirmed mechanism of action (MOA) data from DrugBank or another authoritative source
Preclinical or case-level evidence establishing biological plausibility for acromesomelic dysplasia, Hunter-Thompson type specifically
If no plausible candidate emerges from this rare-disease-heavy prediction set, consider re-running TxGNN with the ordinary/common-disease indication space, where ibuprofen’s known pharmacology is more likely to yield actionable candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.